ICU Medical (NASDAQ:ICUI) Upgraded to “Buy” at StockNews.com

ICU Medical (NASDAQ:ICUI) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

Several other equities analysts also recently weighed in on ICUI. Raymond James set a $97.00 price target on shares of ICU Medical in a research note on Wednesday, March 12th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price on the stock in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, ICU Medical currently has a consensus rating of “Buy” and an average target price of $168.67.

ICU Medical Trading Up 4.0 %

Shares of ICUI stock opened at $149.21 on Tuesday. ICU Medical has a fifty-two week low of $93.36 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The stock’s fifty day moving average is $156.96 and its two-hundred day moving average is $164.86. The firm has a market capitalization of $3.66 billion, a P/E ratio of -32.65 and a beta of 0.73.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 1,373 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total value of $213,474.04. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,262,119.64. This represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ICU Medical

Several institutional investors and hedge funds have recently modified their holdings of the company. Norges Bank acquired a new position in ICU Medical in the 4th quarter valued at about $40,151,000. FMR LLC grew its holdings in shares of ICU Medical by 2,676.6% in the third quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after purchasing an additional 100,345 shares in the last quarter. Point72 Asset Management L.P. increased its stake in ICU Medical by 63.2% during the 4th quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier’s stock worth $38,069,000 after buying an additional 95,030 shares during the period. Dimensional Fund Advisors LP lifted its holdings in ICU Medical by 18.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier’s stock worth $83,788,000 after buying an additional 82,982 shares in the last quarter. Finally, State Street Corp boosted its position in ICU Medical by 9.3% in the 3rd quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after buying an additional 77,506 shares during the period. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.